Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Abstract

PRDXs are antioxidant enzymes that have an important role in cell differentiation, proliferation and apoptosis. We investigated whether PRDX I and VI expression is related to bladder cancer. PRDX I and VI mRNA levels were examined in 149 tumor specimens in patients with primary bladder cancer, in 19 specimens with corresponding normal-appearing bladder mucosa surrounding cancer and in 18 with normal bladder mucosa using real-time polymerase chain reaction. PRDX I and VI expression in bladder cancer (0.6644 and 0.1455 pg/ml) was significantly higher than in normal tissue (0.0278 and 0.0542 pg/ml, each p <0.05) and higher than in corresponding normal bladder mucosa surrounding cancer (0.2353 and 0.0304 pg/ml, respectively, each p <0.0005). PRDX I and VI expression was enhanced in patients with no recurrence (0.8148 and 0.2232 pg/ml) and no progression (0.7405 and 0.1716 pg/ml) compared with levels in those with recurrence (0.4314 and 0.0588 pg/ml) and progression (0.4338 and 0.0668 pg/ml, respectively, each p <0.05). PRDX I and VI expression did not correlate with disease-free survival in patients with bladder cancer. Enhanced PRDX I and VI expression is strongly associated with bladder cancer development. Moreover, enhanced PRDX I and VI expression is also positively associated with a low rate of bladder cancer recurrence and progression. It might be useful as a marker for assessing the recurrence or progression of human bladder cancer.